Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.pdindia.com | |
Market Cap | 10.11 Cr. | |
Enterprise Value(EV) | 116.34 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -25.61 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 38.75 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | -278.81 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | -0.01 | Calculated using Price: 3.39 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 2.98 Cr. | 29,816,300 Shares |
FaceValue | 10 | |
About Parenteral Drugs (India) Ltd. | ||
Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies. |
No Deliveries found
1 Day |
|
|
1 Week |
|
|
1 Month |
|
|
3 Month |
|
|
6 Month |
|
-15.67% |
1 Year |
|
-33.66% |
2 Year |
|
-37.34% |
5 Year |
|
-63.11% |
10 Year |
|
-90.98% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | -44.85 | -23.61 | -46.67 | -152.43 | ||||||
Return on Capital Employed (%) | -5.15 | 1.90 | -2.29 | -8.13 | -6.91 | -5.55 | -35.07 | -52.31 | ||
Return on Assets (%) | -12.80 | -5.44 | -8.41 | -12.60 | -12.16 | -13.17 | -23.45 | -26.72 | -29.65 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 246 | 202 | 127 | 325 | -17 | -136 | -447 | -561 | -683 | -824 | |
Non Curr. Liab. | 427 | 456 | 427 | 440 | 462 | 370 | 4 | -26 | -59 | -91 | |
Curr. Liab. | 162 | 166 | 230 | 300 | 428 | 593 | 878 | 1,006 | 1,144 | 1,201 | |
Minority Int. | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
Equity & Liab. | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 | |
Non Curr. Assets | 629 | 619 | 549 | 902 | 750 | 727 | 368 | 351 | 334 | 219 | |
Curr. Assets | 192 | 200 | 235 | 163 | 122 | 99 | 67 | 67 | 68 | 67 | |
Misc. Exp. not W/O | 14 | 5 | 1 | 1 | |||||||
Total Assets | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 9 | |
Other Income | 0 | 61 | 1 | 2 | 6 | 2 | 1 | 0 | 0 | 0 | |
Total Income | 328 | 334 | 264 | 262 | 236 | 226 | 33 | 32 | 12 | 9 | |
Total Expenditure | -341 | -350 | -248 | -296 | -252 | -225 | -50 | -47 | -24 | -24 | |
PBIDT | -14 | -15 | 15 | -34 | -17 | 0 | -16 | -14 | -12 | -16 | |
Interest | -56 | -60 | -70 | -70 | -86 | -98 | -96 | -110 | -125 | -106 | |
Depreciation | -23 | -19 | -31 | -23 | -25 | -24 | -69 | -17 | -17 | -40 | |
Taxation | -15 | 1 | 19 | 10 | 10 | 10 | 33 | 28 | 33 | 33 | |
Exceptional Items | 47 | 0 | -1 | 0 | 52 | ||||||
PAT | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
Adjusted EPS | -42 | -15 | -23 | -39 | -40 | -38 | -50 | -38 | -41 | -26 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | |
Cash Fr. Inv. | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | |
Cash Fr. Finan. | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | |
Net Change | 5 | -3 | -2 | -5 | 1 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 13 | 11 | 8 | 3 | 5 | 0 | 0 | 0 | 0 | 0 |
Sat, 11 Mar 2023
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) This is to inform you that the Committee of Creditors of Parenteral Drugs (India) Limitedunder CIRP has been formed as on 03/03/2023 and same has been informed to Honble NCLT. |
Sat, 11 Mar 2023
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors This is to inform you that the 1st Meeting of Committee of Creditors of Parenteral Drugs (India) Limited Under CIRP will be held on 13/03/2023 at 4:30 PM through video conference / other audio-visual method. |
Sat, 11 Mar 2023
Corporate Insolvency Resolution Process (CIRP)-List of Creditors This is to inform you that the list of Creditors of Parenteral Drugs (India) Limited Under CIRP has been prepared on 03/03/2023 and uploaded in IBBI Website on 04/03/2023 and the same has been informed to Honble NCLT |
No Scans Found |